Recommendations for the Use of White Blood Cell Growth Factors: American Society of Clinical Oncology Clinical Practice Guideline Update-Reference-Cited by-同舟云学术

Recommendations for the Use of White Blood Cell Growth Factors: American Society of Clinical Oncology Clinical Practice Guideline Update

Published:2015-11 Issue:6 Volume:11 Page:511-513
ISSN:1554-7477
Container-title:Journal of Oncology Practice
language:en
Short-container-title:JOP

Author:

Smith Thomas J.¹,Bohlke Kari¹,Armitage James O.¹

Affiliation:

1. The Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins, Baltimore, MD; American Society of Clinical Oncology, Alexandria, VA; and University of Nebraska Medical Center, Omaha, NE

Publisher

American Society of Clinical Oncology (ASCO)

Subject

Health Policy,Oncology (nursing),Oncology

Link

https://ascopubs.org/doi/pdfdirect/10.1200/JOP.2015.006742

Reference5 articles.

1. Colony-Stimulating Factors for Febrile Neutropenia during Cancer Therapy

2. Patterns of chemotherapy‐associated toxicity and supportive care in US oncology practice: a nationwide prospective cohort study

3. Quantitative Relationships Between Circulating Leukocytes and Infection in Patients with Acute Leukemia

4. Reduction by Granulocyte Colony-Stimulating Factor of Fever and Neutropenia Induced by Chemotherapy in Patients with Small-Cell Lung Cancer

Cited by 26 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. First Line Treatment of Newly Diagnosed Transplant Ineligible Multiple Myeloma: Recommendations from the Canadian Myeloma Research Group Consensus Guideline Consortium;Clinical Lymphoma Myeloma and Leukemia;2023-05

2. Advanced Stage Is a Risk for Severe Neutropenia in Breast Cancer Patients Undergoing Neoadjuvant Adriamycin/Cyclophosphamide/Docetaxel Chemotherapy;World Journal of Oncology;2022-12

3. Colony stimulating factors for prophylaxis of chemotherapy-induced neutropenia in children;Expert Review of Clinical Pharmacology;2022-08-03

4. The survival impact of palliative chemotherapy dose modifications on metastatic colon cancer;BMC Cancer;2022-07-04

5. Real-world cost–effectiveness of primary prophylaxis with G-CSF biosimilars in patients at intermediate/high risk of febrile neutropenia;Future Oncology;2022-05